EGFR and cancer: To gain further pathway and functional insight into possible genetic interactions underlying ARID1A deficiency-driven resistance to anti-EGFR therapy, we next searched for oncogenic dependencies or mutual exclusivities between ARID1A mutations and other alterations in cancer.